{
    "nct_id": "NCT03020602",
    "official_title": "A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen",
    "inclusion_criteria": "* Be ≥ 18 years of age\n* Have a life expectancy ≥ 6 weeks\n* Have a Karnofsky Performance Score (KPS) ≥ 60\n* Have pathologically proven GB, gliosarcoma (WHO IV), or anaplastic astrocytoma (WHO III) in recurrence after treatment with bevacizumab\n* Be at least 14 days from the last administration of bevacizumab\n* Be at least 28 days from last administration of cytotoxic chemotherapy or other investigational agent\n* Have received radiation therapy with concurrent temozolomide. Total radiation dosage can range from 5400 to 6000 cGy administered in daily fractions of 150 to 200 cGy over 6 weeks, or the equivalent in a hypofractionated protocol (for example, 4000cGy in 15 fractions or 2500cGy in 5 fractions). Patients who are MGMT negative do not need to have received temozolomide.\n* Have adequate organ and marrow function as follows (all required):\n\n  * ANC ≥ 1500 mm3\n  * Platelets ≥ 100,000/mm3\n  * Hemoglobin ≥ 9 g/dL\n  * Serum creatinine ≤ 1.8 mg/dL or creatinine clearance > 50 mL/min Bilirubin ≤ 1.5 mg/dL\n  * Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)\n  * Aspartate transaminase (AST) ≤ 2.5 x ULN\n  * Prothrombin time (PT) ≤ 1.5 x ULN\n  * International Normalized Ratio (INR) ≤ 1.5 x ULN\n  * Partial thromboplastin time (PTT) ≤ 1.5 x ULN\n* Subjects of childbearing potential must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a history of spontaneous or tumor related cerebral hemorrhage; or has cerebral hemorrhage as determined by the screening FDG PET CT and MRI. This does not include stable post operative blood products seen on a gradient echo MRI sequence.\n* Has the any of the following cardiac history:\n\n  * Active heart disease including myocardial infarction within previous 3 months\n  * Symptomatic coronary artery disease\n  * Arrhythmias not controlled by medication\n  * Unstable angina pectoris\n  * Uncontrolled or symptomatic congestive heart failure (NYHA class III and IV) 3.2.3 Uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months, including any of the following, but not limited to:\n  * Epistaxis\n  * Hemoptysis\n  * Hematochezia\n  * Hematuria\n  * Gastrointestinal bleeding\n  * Spontaneous or tumor related intracranial hemorrhage\n* Known predisposition for bleeding such as von Willebrand's disease or other such condition(s)\n* Uncontrolled concurrent illness that would limit compliance with study requirements, including any of the following, but limited to:\n\n  * Uncontrolled infection.\n  * Psychiatric illness/social situations\n* Prior malignancy except for non melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 3 years prior to 1st dose of investigational drug\n* Receiving any of the following medications:\n\n  * Therapeutic doses of any anticoagulant, including low molecular weight heparin (LMWH). Concomitant use of warfarin, even at prophylactic doses, is prohibited\n  * Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids.\n  * Colony stimulating factors (CSFs) that cannot be held during the monitoring period for dose limiting toxicities (DLT)\n* Has significant toxicities from prior treatment that have not resolved or stabilized\n* Known allergy to Coenzyme Q10\n* Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K\n* Is pregnant or lactating\n* Known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible.",
    "miscellaneous_criteria": ""
}